Immune system response to tetanus, diphtheria, pertussis, and poliovirus antigens (DTaP-IPV/Tdap-IPV response)

The immune system response to tetanus toxoid, reduced diphtheria toxoid, acellular pertussis antigens, and inactivated poliovirus antigens is a complex physiological process rather than a single molecular target. This response involves the coordinated activation of the adaptive immune system to provide protection against four major infectious diseases: tetanus, diphtheria, pertussis, and poliomyelitis (CDC, 2023). Upon administration of these antigens, typically via combination vaccines like DTaP-IPV or Tdap-IPV, antigen-presenting cells process the toxoids and viral proteins to stimulate T-helper cells and B-lymphocytes (StatPearls, 2023). This interaction leads to the production of high-affinity neutralizing antibodies and the establishment of long-term immunological memory. The efficacy of this response is clinically measured by assessing serum antibody titers against each specific pathogen component (FDA, 2022). While highly effective for public health, stimulating this response can lead to common side effects such as localized inflammation or systemic symptoms like fever. This 'target' is primarily used in clinical trial contexts to define the endpoint of vaccine immunogenicity studies rather than to identify a specific drug-binding protein.

Other names

Immune response to DTaP-IPVImmune response to Tdap-IPVActive immunity to Tetanus, Diphtheria, Pertussis, and PolioVaccine-induced immunity to DTP-polio

Active immunization via the induction of neutralizing antibodies and cell-mediated immune memory against bacterial toxins (tetanus and diphtheria), bacterial components (pertussis), and viral antigens (poliovirus types 1, 2, and 3).